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Abstract 
Niemann-Pick type C (NP-C) is a rare recessive disorder associated with progressive 
supranuclear gaze palsy. Degeneration occurs initially for vertical saccades and later for 
horizontal saccades. There are studies of oculomotor degeneration in adult NP-C patients [1, 
2] but no comparable studies in children.  We used high-resolution video-based eye tracking 
to record monocular vertical and horizontal eye movements in 2 neurological NP-C patients 
(children with clinically observable oculomotor abnormalities) and 3 pre-neurological NP-C 
patients (children without clinically observable oculomotor abnormalities). Saccade onset 
latency, saccade peak velocity and saccade curvature were compared to healthy controls 
(N=77).  NP-C patients had selective impairments of vertical saccade peak velocity and 
vertical saccade curvature, with slower peak velocities and greater curvature. Changes were 
more pronounced in neurological than pre-neurological patients, showing that these 
measures are sensitive to disease progress, but abnormal curvature and slowed downward 
saccades were present in both groups, showing that eye-tracking can register disease-related 
changes before these are evident in a clinical exam. Both slowing, curvature and the detailed 
characteristics of the curvature we observed are predicted by the detailed characteristics of 
RIMLF population codes. Onset latencies were not different from healthy controls.  High-
resolution video-based eye tracking is a promising sensitive and objective method to measure 
NP-C disease severity and neurological onset. It may also help evaluate responses to 
therapeutic interventions. 
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Niemann-Pick Disease type C (NP-C, OMIM #257220) is a lysosomal storage 
disorder caused by abnormal intracellular lipid accumulation which results from  a mutation 
in genes encoding either NP-C1 (95% of patients) or NP-C2 (5%) proteins [3, 4]. Clinical 
symptoms of NP-C are progressive and are primarily neurological. One of the earliest, and 
most distinct, neurological symptoms of NP-C is vertical supranuclear gaze palsy (VSGP) 
[5–7].  Initially only vertical eye-movements are affected, but later both horizontal and 
vertical movements become abnormal [8]. This results from cell loss in the rostral interstitial 
nucleus of the medial longitudinal fasciculus (RIMLF), responsible for vertical saccades, and 
eventually in the paramedian pontine reticular formation (PPRF), responsible for horizontal 
saccades. The integrity of excitatory burst neurons in these nuclei is related to peak saccade 
velocity, which has been shown to be a useful index of dysfunction in the RIMLF and PPRF 
[9, 10].  In addition, a strictly upward movement requires balanced excitation in two 
populations of neurons.  Neurons in RIMLF that code upward and left torsion must be 
balanced by neurons that code upward and right torsion so that the two torsional instructions 
cancel out [10].  Damage that is distributed over RIMLF will often produce asymmetries in 
the two populations coding for vertical movements.  We will show that the details of RIMLF 
population coding, as described by Crawford and Vilis [11] in their stimulation and activation 
study, predict both the slowing and curvature that we see in our NP-C results. Our results, as 
a consequence, add evidence to support the functional description they provide. 
Detailed reports of oculomotor dysfunction exist in adult NP-C patients [2, 8], where 
vertical saccade degeneration is absolute. Detailed information about the onset and 
progression of vertical saccade degeneration during early stages of the disease, most often in 
childhood, is lacking. This is a clinically important gap because the only approved treatment 
of NP-C (miglustat, or Zavesca, Actelion, a small iminosugar that inhibits glucosylceramide 
synthesis) slows neurodegeneration [12–15] but is prescribed only once neurological 
involvement (e.g. gaze palsy or ataxia) has been detected. Established clinical severity scales 
aimed at tracking the neurological progression of NP-C exist [16]. However, these are based 
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on a bedside examination of eye movements.  Bedside examination will not be able to 
measure changes with the same sensitivity as modern eye-trackers which sample eye position 
up to 1000 times a second.  These offer the potential to detect the eye movement changes 
much earlier.  We tested techniques designed to identify changes to eye movements, and, 
therefore, the onset of neurodegeneration earlier. This could allow clinicians to make 
decisions sooner that are aimed at maintaining patient abilities at the highest possible level.  
In this study, we established norms for oculomotor developmental change in a large sample 
of control children and compared NP-C patients to the control range to see if this allowed 
neurological impairment to be detected using eye-tracking before it is evident with standard 
clinical methods.  
 
Methods 
Patient Information. Five paediatric NP-C patients were recruited from NP-C clinics at 
Birmingham Children’s Hospital and Great Ormond Street Hospital (mean age= 6.3, 
range=2–9years, M/F=3/5). Inclusion criteria included a diagnosis confirmed by cultured 
fibroblasts cholesterol esterification rate analysis and filipin staining of unesterified 
cholesterol. In addition, patients must have been aged above 2-years and be neurologically 
capable of attending to the oculomotor assessment. There were no other exclusion criteria 
(e.g. none related to oculomotor control).  Clinical scores were obtained for patients using 
Yanjapnin NP-C Clinical Severity Scale [7]. Demographics and overall clinical scores are 
shown in Table 1 (detailed clinical scores in Appendix A). Three patients were neurologically 
asymptomatic and, in particular, did not have oculomotor abnormalities in clinical testing 
(pre-neurological NP-C, disability score=0).  The two neurological patients (NP-C03 and 
NP-C05) had clinically observable mild/functional VSGP (i.e. vertically eye movements were 
not completely abolished, but initiation depended on the use of a proceeding head-thrusting 
and/or blinking).  No patients were receiving medication for seizures (e.g. benzodiazepines) 
that could disrupt eye movements. Patients were compared to data from 77 healthy controls 
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with no history of major medical, neurological or psychiatric illness (mean age=11.86, 
range=2–20 years, M/F=43/34). 
_________________ 
Table 1 about here 
_________________ 
Procedure. The study was approved by the local research ethics committee (South 
Birmingham LREC) and patient parents/guardians provided written informed consent. 
Participants were tested in a dimly lit environment, 60 cm away from a 32 × 26 cm CRT-
monitor (resolution=1024 by 768; refresh rate=60 Hz). Monocular eye movements were 
recorded at 1000 Hz (video-based EyeLink® 1000, tower mount; SR Research Ltd.). Eye 
movements were calibrated to an accuracy of at least 1º of visual angle.  A chin rest was used 
to stabilize each participant’s head in relationship to the camera monitoring the position of 
the pupil and corneal reflection. 
The oculomotor task consisted of 48 trials.  Trials began with the target, an elephant 
face (size=1.5º), presented centrally for 1000 milliseconds (ms). The target disappeared and 
reappeared at one of four surrounding locations (above, below, left and right; 
eccentricity=10º) for 1000ms. Participants were instructed to fixate the elephant and follow it 
quickly and accurately when it moved.  For younger participants (2-5 years), interstimulus 
intervals included a salient animated cartoon flower that rotated at the centre of the screen to 
increase task engagement and reduce inattention.  
 
Statistical Analysis. Raw data were plotted to identify saccades visually. The first eye 
movement toward the target was marked, along with the 1000 samples that immediately 
preceded and followed the movement. These 1000 samples, where the eye was relatively 
stable, were used to calculate a velocity threshold (velocity mean ± 3SD) that allowed the 
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saccade to be systematically identified.  Trials where blinks disrupted saccadic movements 
were eliminated.  
Development of saccade onset latency, saccade peak velocity and saccade curvature 
in healthy controls was characterised using developmental trajectories [17]. For each 
measure, three functions (a constant value, or intercept only, linear and quadratic functions) 
were fit to control data and the best was selected using Akaike Information Criterion values 
(AIC) and Akaike weights [18]. AIC-based model selection is preferable to model selection 
using p-values because it emphasizes the weight of evidence for models in a candidate set. 
One model or several models can receive support and there is an explicit trade-off between fit 
and number of model parameters to guard against overfitting [18][9].  This method 
distinguishes cases where several models provide relatively good accounts of the data 
(relatively equal probabilities split across several models) from cases where one model is 
clearly better than the others (one model has high probability, all others low). 
We used linear mixed effects models (LME) for statistical analysis of 
developmental trajectories and group differences [19].  Random and fixed effects were 
selected using AIC following the method described by Diggle [20].  We report group 
analyses for pre-neurological patients, where we want to know if eye-tracking can 
reveal group differences that are not clinically apparent (and don’t depend on the most 
severe patients).  We expect to see differences between neurological  patients and 
controls, and, in fact, these are usually apparent at the level of individual patients.  We 
report individual results for all patients.  In the group analysis, there were fixed effects 
for Group (to test for differences between patients and controls), Age (to test for 
differences in developmental trajectories) and Condition (to test whether abnormalities 
were confined to particular stimulus locations).  Main effects of Group are found if 
performance is worse in the patient group across all ages. Interactions with Age occur if 
development is slower in the patient group, if it is slower at a particular stimulus location 
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(Age X Group or Age X Condition interactions) or if the developmental trajectory is slower 
for patients in only some conditions (Age X Condition X Group interaction).  
To examine performance in individual patients, we, first, calculated ninety-five 
percent prediction intervals for developmental trajectories in controls by fitting intercept-
only, linear and quadratic functions to upper or lower 95% t-value cutoffs. We used AIC to 
choose the function that best described the trajectory of the upper or lower limit. Individual 
NP-C patients who were outside the prediction interval were reliably different from controls.  
Individual patients were compared to controls using the equivalent of z-scores, calculated 
from the upper or lower endpoints of the prediction intervals, rather than from noisier age-
specific samples. Our method smooths the prediction intervals, borrowing information from 
adjacent regions on the developmental curve, in the same way the function describing the 
mean is smoothed. We label these zpi.1 
 
Results 
Saccade Onset Latency. Saccade onset latency in normally developing control children was 
described best by a quadratic function (quadratic ΔAIC/AICw 0/.99; linear ΔAIC/AICw = 
13.04/.01; intercept ΔAIC/AICw = 26.48/.01).  Developmental change occurred between 2 
and 10 years with little improvement after 10 (Figure 1). The rate of development differed 
across target locations. LME analysis (random intercept for participants), revealed an 
interaction between target location and age (Condition X Age2 model ∆AIC/AICw = 0/.99; 
Condition + Age 2 model = 13.83/.00;  detailed model results in Appendix B). To see if 
trajectories were systematically grouped, a model distinguishing horizontal from vertical 
trajectories was compared to a model with trajectories for each target location. Both models 
                                                 
1 Specifically, for values above the mean, 𝑆𝐷௣௜ = (𝑃𝐼௨௣௣௘௥ − 𝑚𝑒𝑎𝑛)/1.96 and 𝑧௣௜ = 𝑌௣௔௧௜௘௡௧/𝑆𝐷௣௜ , 
where 𝑃𝐼௨௣௣௘௥= upper boundary of the 95% prediction interval; mean = the mean predicted by the fit to control 
values; and 𝑌௣௔௧௜௘௡௧ = patient’s observed data value. Values below the mean were calculated in the same way 
except the 95% prediction interval boundary (𝑃𝐼௟௢௪௘௥) used the lower boundary since boundaries were not 
necessarily symmetric. 
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provided equivalent descriptions of healthy development (ΔAIC < 1), so the simpler 
horizontal/vertical model was preferred. Onsets were initially slower but development was 
steeper for vertical target positions (Figure 1). 
_____________________ 
Figure 1 about here 
_____________________ 
 
Evidence of a difference between pre-neurological NP-C patients and controls was 
weak.  The model with strongest support did not distinguish patient and control groups 
(Condition X Age2 model ∆AIC/AICw = 0/.52; strongest model with group effect: Condition 
X Age2+ Group  model = 1.38/.26; model results are listed in Appendix C), and mean pre-
neurological patient onset times were normal (mean zpi horizontal = 0.53 / vertical = - 0.17). 
Results for individual patients did not highlight significant exceptions to this pattern. 
Only the onset time of the youngest pre-neurological patient (2 years) was longer than 
expected (zpi = -2.17) and for left targets only. Deficits or borderline deficits were more 
apparent in the vertical movements of neurological patients. They were slower to initiate 
saccades (NPC-03, zpi = -2.17; NPC-05, zpi = -2.16).  
 
Saccade Peak Velocity. Peak velocity, on average, slowed somewhat with age, and the 
amount of change depended on the quadrant.  The best model was linear (Condition X Age 
model ∆AIC/AICw = 0/.86; Condition + Age model ∆AIC/AICw = 3.6/.14).  Previous studies 
reporting velocity changes with age have differed [see review in 21], but slowing in the early 
years is one of the reported patterns [e.g. 22], so this is not an isolated result.  
Eye movement peak velocities depend on how far the eyes move.  Velocities are 
systematically higher for longer saccades.   This raises the question of whether developmental 
differences in peak velocity were driven by differences in saccade amplitude.    To factor out 
the influence of amplitude, which will also be important when we turn to patient data, we 
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predicted peak velocity using amplitude and then modelled the component of velocity left 
over after amplitude was factored out (velocity residuals). 
There was still an interaction between age and condition (Condition X Age model 
∆AIC/AICw = 0/.98; Condition + Age model ∆AIC/AICw = 8.6/.01).  Velocity decreased 
with age, but only for downward saccades (Age model ∆AIC/AICw = 0/.99; intercept only 
model ∆AIC/AICw = 10.6/.005; Figure 2A).   Other directions did not change (left: intercept 
only model ∆AIC/AICw = 0/.66; Age model ∆AIC/AICw = 1.3/.34;  right: intercept only 
model ∆AIC/AICw =  0/.67; Age model ∆AIC/AICw = 1.4/0.33; top: intercept only model 
∆AIC/AICw = 0/.72; Age model ∆AIC/AICw =1.9/.28). 
Amplitude was also an issue when quantifying group differences in peak velocity.  
Patients could have lower peak velocities either from slowing or simply because saccades 
often fell short of their targets.  Plotting saccade amplitude and velocity together in Figure 2B 
shows that changes in velocity were not generally a simple consequence of making shorter 
saccades.  Confidence intervals describing the control range of amplitudes and peak 
velocities (error bars) show that, for bottom targets, 3 patients were slower than controls, but 
only one had abnormally shortened saccades.  For top targets, two patients were slow, but 
only one made shorter saccades.  Our group analyses factor out these amplitude differences, 
by using velocity residuals, to quantify the component of velocity that is independent of the 
length of the saccade. 
After factoring out amplitude differences, pre-neurological patients were slower than 
controls, but not in all positions, resulting a Group X Condition interaction (all of the top 3 
models, which only differed by a maximum ΔAIC of 1.23, included a Group X Condition 
interaction).  The first model without the interaction was clearly worse (Condition X Age + 
Group X Age ΔAIC/AICw=3.8/.06).  Pre-neurological patients were slower than healthy 
controls for bottom targets only (Age + Group ΔAIC/AICw=0/.99; Age only 
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ΔAIC/AICw=10.4/.006). There were no differences at other target locations (intercept-only 
model always better).   
In individual results, deficits were more pronounced in neurological compared to pre-
neurological patients. Peak velocity of downward saccades was clearly slower in both of the 
neurological patients (filled symbols; NPC-03, zpi=-3.10; NPC-05, zpi =  -4.11).  It was also 
slower in the eldest pre-neurological patient (NPC-04, zpi = -2.37; pre-neurological patients 
are open symbols). In the other directions, peak velocities of both pre-neurological and 
neurological patients were mostly within the range of controls, although there was some 
evidence of slowing in horizontal movements for the two neurological patients (NPC-03, 
right zpi= -2.31; NPC-05, left zpi=-1.53).  
________________ 
Figure 2 about here 
________________ 
 
Saccade Curvature.  Raw eye movement data revealed marked curvature in patient 
saccades. Figure 3 illustrates how curved vertical saccades had become. Horizontal saccades 
were unaffected when compared to age-matched controls. 
________________ 
Figure 3 about here 
________________ 
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To quantify curvature and compare patients to healthy controls we measured eye 
position on the dimension orthogonal to the saccade (e.g. horizontal for vertical saccades). 
The standard deviation of this value summarised the degree of curvature. 
In healthy controls, development with age was best captured by a linear function  
(Linear ΔAIC/AICw=0/0.91; Quadratic = 4.8/0.09; Intercept only = 67.6/0.00; Figure 4).  
There was an interaction between age and target location (Condition X Age model 
∆AIC/AICw = 0/.92; Condition + Age model = 4.85/.08; Condition model = 20.1/0.00).  To 
see if trajectories were systematically grouped, a model coding each direction separately was 
compared to a model that only distinguished horizontal and vertical movements. The 
Separate model provided the best description (Separate model = 0.00 / 1; Horizontal/vertical 
model ΔAIC / AICw = 55.4 / 0).  Downward movements showed most developmental 
change, followed by left, upward and then right (which had very little change with age).   
Downward movements also showed the largest absolute levels of curvature, followed by 
upward movements.  Left and right movements were least curved and nearly equal.  It is 
worth noting that the differences in controls are small, even if they are statistically reliable. 
________________ 
Figure 4 about here 
________________ 
Comparing pre-neurological patients and healthy controls showed differences at 
particular locations (Condition X Age X Group model = ∆AIC/AICw = 0/0.48, Condition X 
Age + Condition X Group model = 1.68/0.21, Condition X Age +  Condition X Group  + Age 
X Group model = 1.73/0.20).  Group differences were most pronounced for bottom targets 
(∆AIC/AICw: Age X Group model = 0/0.83; Age model = 3.4/0.15), but top targets were 
different as well (∆AIC/AICw: Age X Group model = 0/0.55; Age model = 1.3/0.28).  There 
was no effect of group for left or right targets ((∆AIC/AICw: left: Age model = 0/0.74; Age X 
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Group model = 2.1/0.26; right: Intercept only model = 0/0.52; Group model = 1.5/0.25).  The 
scale of the change in curvature in vertical movements is evident in Figure 3. 
Individually, both neurological patients and 2 of 3 pre-neurological patients were 
outside the normal range of curvature for vertical saccades (Figure 4, bottom). Both 
neurological patients had substantially curved downward saccades (NPC-03, zpi = -26.74; 
NPC-05,  zpi = -5.65), but also clear upward changes (NPC-03, zpi = -16.37; NPC-05,  zpi = -
2.60). Two pre-neurological patients also exhibited clear changes in upward and/or 
downward movements (NPC-02, upward, zpi = -3.19; NPC-04, upward, zpi = -3.26, downward 
= -2.28). The unaffected patient was the youngest of the pre-neurological group (NPC-01, zpi 
= -0.19).   
Table 2 summarises results from all measures in all directions.  Horizontal movements are 
almost entirely unaffected by the disease.  Vertical movements are often affected.  Curvature 
is affected first, with changes apparent even in pre-neurological patients and peak velocity is 
also often affected.  Saccade onset can be affected, but usually only when the disease is more 
advanced. 
Discussion 
We have presented a high resolution assessment of oculomotor function from a cohort 
of paediatric neurological and pre-neurological NP-C patients (i.e. with and without 
clinically apparent oculomotor impairments). In both groups of patients there were 
impairments in saccade velocity and saccade curvature. Vertical saccades were more affected 
than horizontal saccades as would be expected with greater cell loss in the brainstem nucleus 
RIMLF compared to the PPRF [12]. 
 
Since excitatory burst neurons in the RIMLF are associated with peak saccade 
velocity and that RIMLF is known to be affected by the disease, velocity is a natural place to 
look for early signs of NP-C damage [12].  Velocity changes were, indeed, found in all of the 
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neurological patients, as expected, and in one of the three pre-neurological patients.    This is 
exactly the pattern that is desirable for a good indicator.  Changes were apparent in eye-
tracking records before they were noticeable in the clinic, and they followed the pattern you 
would expect from a value that anticipates more serious changes to oculomotor control (i.e. 
the changes were apparent in the older patients, where the disease is likely to be more 
advanced, but less strong in younger patients) The lag with which subtle changes to peak 
velocity anticipate more substantial changes and the consistency of this lag across individuals 
is an important topic for future research. 
A new result was that saccade curvature was an equally early or even earlier  index of 
changes. Curved eye-movements to oblique targets have been reported previously in NP-C 
[23], but, given the way the eye-movement system is organised, curved saccades to oblique 
targets are expected when vertical movements are slowed. Oblique saccades become curved 
because the eye arrives at the horizontal target position earlier than the vertical position and 
the trajectory curves upward as the vertical component finishes late.  In other words, 
curvature in oblique saccades is a simple consequence of velocity changes.  Curved oblique 
saccades do not, however, predict that purely vertical saccades will also be curved. These 
should just be slower.  We found that purely vertical saccades were curved, which cannot be 
explained by simple velocity changes. 
Curved vertical saccades have been noticed before. Quinn [14] and Jitkritsadakul, 
Tansuhaj & Bhidayasiri [15] reported that early stage progressive supranuclear palsy (PSP) 
patients had curved saccades in the purely vertical direction.  Leigh [16] speculated that this 
is an adaptive strategy whereby the patient starts to make a saccade with a horizontal 
component to increase the time available to generate the vertical component. Indeed, a recent 
case report describes an adult with NP-C who had severely affected downward saccades and 
upward saccades accompanied by a horizontal movement, which the authors interpreted as a 
strategic adjustment [24]. While an element of strategy cannot be ruled out in our patients, 
curvature was evident before vertical saccades were noticeably slower and the degree of 
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curvature was relatively small, compared to what would be detectable without an eye-tracker, 
so a strategic approach seems unlikely.  The neural organisation of RIMLF, however, offers a 
better explanation. 
Curved saccades are predicted from the way the RIMLF nucleus is organised to code 
vertical movements.  Neurons in the RIMLF do not code up- or downward movements in 
isolation. Instead each neuron codes both a direction (up/down) and a rotation around the axis 
that runs from the pupil down the line of sight (torsion) [11]. This is because vertical 
movements involve the oblique muscles, which are the main muscles responsible for 
torsional movements, in addition to the inferior and superior rectus muscles that move the eye 
directly up and down.   
Crucially, Crawford and Vilis [11], in their detailed study of RIMLF function, show 
that the neuronal populations dedicated to vertical  movements do not code simple straight up 
and straight down directions.  They code an oblique up or oblique down direction in addition 
to torsion (see their Figures 7 and 16).  Normally, when RIMLF is coding straight vertical 
movements, the left and right oblique deflections cancel each other, in the same way that the 
torsional movements cancel, and movement is straight up or straight down.  When one side of 
the RIMLF is inactivated, however, Crawford and Vilis noted that eye-movements had a left 
or right deflection in addition to slowing in the vertical direction.  This means the coding 
system predicts exactly what we found in patients.  When populations of neurons that must 
normally counterbalance are affected by disease, the eyes will be driven obliquely toward the 
side pointed to by the stronger population.   
This explains the initial deflection, but not the return to the target.  For the eyes to 
curve back toward the target position, eye-movements must be under the feedback control of 
an unaffected centre above the level of the RIMLF.   In other words, there must be a level 
where the target is coded in the correct position that will force a correction. This also fits, 
however, current standard assumptions about eye-movement control [10, 25].  The exact 
details of how and where feedback control is implemented are still under investigation, but 
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there is agreement that a copy of the signal from RIMLF (a corollary discharge, which will 
contain the oblique error) is compared to the intended eye-position (under control of the 
superior colliculus) and the eye position is modulated until the error is eliminated [10, 25]. 
Two additional predictions follow from these accounts.  The first is that curvature will 
be systematically to one side for up or down saccades and the second is that curvature will 
begin at the start of the saccade.  Neither of these would follow from a source of 
measurement noise or an artefact that affects vertical measurements.  It is clear from Figure 3 
that both of these predictions were substantially upheld (only NP-C 03’s upward saccades 
showed curvature on both sides of the vertical, and this is one of the most severe patients).  In 
fact, movements up and down are not only consistently to one side, they tend to be curved to 
opposite sides for up and down movements.  This is what Crawford and Vilis found when 
they inactivated one side of the RIMLF at a time.  Horizontal deflections were to opposite 
sides for up and down saccades. 
We assume, in the absence of other information, that NP-C will randomly affect 
populations of neurons in the RIMLF.  Random damage is not guaranteed to affect one side 
of the nucleus more strongly, but that will often be the case.  Following the logic of random 
damage affecting a bilaterally arranged structure, it should be possible for damage to be 
relatively equally spread across right and left RIMLF.  This means that slowed saccades 
without curvature are possible, but should occur relatively rarely.  In addition, as damage 
progresses, curvature could become either  more or less pronounced.  It is not guaranteed that 
the asymmetry will always get worse with time.  As damage becomes more complete, in fact, 
there may be a tendency for slow or hypometric saccades to dominate, with curvature a less 
prominent feature. 
As damage to RIMLF progresses, the total number of burst neurons firing in any part 
of the RIMLF will get noticeably smaller. Velocity and, eventually, saccade onset itself 
should be affected. This was the pattern we observed (see Table 2).  The early appearance of 
curved saccades and velocity changes raises the possibility that video-based oculomotor 
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measurement could improve the sensitivity with which disease progression is tracked in NP-
C [see also 9].      
Our results show that high-resolution eye tracking has the potential to: 1) Provide 
sensitive metrics that track the course of neurodegeneration in paediatric NP-C patients, and 
2) Identify the onset of neurological decline earlier than is currently possible with standard 
clinical approaches. This is particularly important for NP-C management since treatment, 
which slows neurological decline, is currently available only when there are measurable 
neurological effects. Our methods could detect onset of neurological decline earlier, so that 
patients are stabilized at a higher level of cognitive function. Sophisticated eye-tracking 
techniques, which have been the domain of specialised laboratories in the past, could move 
into clinical settings and contribute to sensitive assessments. 
NP-C is a rare paediatric neurodegenerative disorder.  Inevitably, this means there is 
some uncertainty about how well our results will generalise to a larger population of patients 
and about how well cross-sectional data reflects what happens, over time, in individuals.  
Note, however, that our method for comparing individual patients to the control population is 
what is needed for clinical decision-making.  This measures when performance in an 
individual is exiting the range defined by a large population of normally developing control 
children.  The control sample is large enough that our confidence in the normal range of 
control values can be relatively high.  It is true that our group comparisons are based on small 
samples of patients, but there are already reliable differences in velocity and curvature based 
on the five patients that we report and the results are theoretically consistent with what is 
known about how RIMLF functions. Additional participants are unlikely to change the 
qualitative pattern that is emerging here, where abnormalities in eye-movements occur, 
although the exact scale and time course and the variability of changes will need to be 
followed in a larger sample.  Longitudinal follow-ups could help us to understand the natural 
time course and degree of individual variability in the disease. Longitudinal data may also 
allow us to detect neurological involvement even earlier than we have been able to do here.  
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This is because an individual’s trajectory of change could be noticeably abnormal before the 
absolute level of performance, at any single point, has exited the control range. 
 
Conclusion. High-resolution video-based eye-tracking, using simple fixation tasks, can 
identify oculomotor changes in NP-C children earlier than is possible with clinical 
oculomotor assessments. A promising new metric, saccade curvature, measured impairments 
in patients both with and without diagnosed neurological involvement and peak velocity was 
also low in some pre-neurological patients. Longitudinal studies should be used to confirm 
our measures as a good marker of neurological onset and explore using them to monitor 
treatment effects in children with NP-C.  Eye-tracking is high precision, but the tasks are 
relatively simple, quick and easy for children to do. Comparison with robust control data can 
highlight individuals who fall outside the normal range, and the approach we have outlined 
here is ideal for both clinical decision-making and working with data from rare diseases. 
Future studies could investigate the utility of eye tracking data to screen for NP-C in 
populations of patients that present with symptoms that are associated NP-C, for example,  in 
patients with early-onset ataxia and / or frontotemporal dementia.  It is thought that NP-C 
may be undiagnosed in some patient groups that display symptoms associated with NP-C, but 
where the symptoms are not diagnostic on their own [26–28] .  Eye-tracking measures could 
contribute to identify those patients that warrant further follow-up investigation. 
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Table 1.  NP-C patient demographics and neurological scores. 
Patient 
Number Gender 
Age 
(Years) 
Disease 
Specific 
Treatment 
Age at  
presentation of 
neurological 
features (Years) 
Disability 
score (0-61) 
NP-C 01 F 2 - - 0 
NP-C 02 M 4 - - 0 
NP-C 03 M 8 Miglustat 7 12 
NP-C 04 M 8.5 - - 0 
NP-C 05 F 9 Miglustat 2 18 
M=male ; F=female 
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Table 2. zpi values for individual patients compared to the control population.  L/R = left/right movements.  D/U = downward/upward movements.  -1.66 = 90% 
cutoff for normal range; -1.96 = 95% cutoff for normal range; -2.37 = 99% cutoff for normal range.  zpi < -1.5 are shown. 
 
Patient 
Number
L R L R D U D U D U
NP-C 01 2 No -2.17 - - - - - - - - -
NP-C 02 4 No - - - - - - - - - -3.19
NP-C 04 8.5 No - - - - - - -2.37 - -2.28 -3.26
NP-C 03 8 Yes - - - -2.16 -2.17 - -3.1 -2.83 -26.74 -16.37
NP-C 05 9 Yes - - -1.53 - - -2.16 -4.11 -3.36 -5.65 -2.6
Horizontal movements Vertical movements
Saccade 
Onset
Saccade 
Velocity
Saccade 
Curvature
Saccade 
Onset
Saccade VelocityAge (Years)
Neuro 
Involvement
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Figure 1.  Developmental trajectory of saccade onset latency to targets in horizontal and 
vertical positions (msec; neurological patients=filled symbols; pre-neurological patients = 
open symbols; controls=open circles).  The solid line represents the mean onset based on a 
quadratic fit.  Dashed lines represent the boundaries of a 95% prediction interval. 
 
Figure 2. Saccade peak velocity (measured in degrees of visual angle/sec). A) Developmental 
trajectory of velocity residuals after amplitude has been factored out.  Left and right saccades, 
like upward saccades, did not change with age and have not been included.  Open circles are 
controls, black circles are pre-neurological patients and grey triangles are neurological 
patients.  B)  Saccade velocity and amplitude plotted together.   Filled symbols are 
neurological patients, open symbols are pre-neurological patients, and error bars represent 
95% prediction intervals for controls. 
 
Figure 3. Saccade curvature to left/right/up/down targets (light grey = 95% prediction interval 
for NP-C trajectories;  dark grey = 95% prediction interval for control trajectories; lines = 
individual saccade traces).   
 
Figure 4. Developmental trajectories for the standard deviation of saccade curvature (in 
degrees of visual angle.  Filled symbols are neurological patients, open symbols are pre-
neurological patients and open circles are controls).  The solid line is the control mean based 
on a linear fit.  Dashed lines are boundaries of the 95% prediction interval. 
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Appendix A. Table of patient clinical severity scores based on the Yanjanin clinical scale 
(2010). 
Domain Function (scale) NP-C 01 NP-C 02 NP-C 03 NP-C 04 NP-C 05 
Major 
Eye-movements (0-5) 0 0 1 0 2 
Ambulation (0-5) 0 0 1 0 1 
Speech (0-5) 0 0 0 0 1 
Swallowing (0-5) 0 0 1 0 2 
Fine Motor Skills (0-
5) 
0 0 2 0 4 
Cognition (0-5) 0 0 3 0 3 
Hearing (0-5) 0 0 1 0 2 
Memory (0-5) 0 0 0 0 1 
Seizure (0-5) 0 0 0 0 0 
Minor 
Gelastic cateplexy (0-
2) 
0 0 0 0 0 
Narcolepsy (0-2) 0 0 1 0 1 
Behaviour (0-2) 0 0 1 0 0 
Psychiatric (0-2) 0 0 0 0 0 
Hyperreflexia (0-2) 0 0 1 0 1 
Incontinence (0-2) 0 0 0 0 0 
Auditory Brainstem 
Response (0-2) 
0 0 0 0 0 
Respiratory (0-2) 0 0 0 0 0 
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Appendix B.   Model results for control participants. 
Model ΔAIC Akaike weight
Saccade onset
Condition X Age2 0.00 0.999
Condition + Age2 13.83 0.001
 Age2 24.52 0.000
Condition 71.09 0.000
Intercept only 81.71 0.000
Peak velocity after amplitude is factored out
Condition X Age 0.00 0.978
Condition + Age 8.59 0.013
Condition 9.51 0.008
Age 290.00 0.000
Saccade curvature
Condition X Age 0.00 0.918
Condition + Age 4.85 0.081
Condition 20.13 0.000
Age 53.05 0.000  
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Appendix C.  Models comparing pre-neurological NPC patients and controls. 
Model ΔAIC Akaike weight
Saccade onset
Condition X Age2 0.00 0.519
Condition X Age2 + Group 1.38 0.260
Condition X Age2 + Group X Age2 3.25 0.102
Condition X Age2 + Group X Condition 4.07 0.068
Condition X Age2 + Group X Condition + Group X Age 5.80 0.029
Condition X Age2 X Group 6.34 0.022
Peak velocity after amplitude is factored out
Condition X Group + Condition X Age + Group X Age 0.00 0.414
Condition X Group X Age 1.00 0.251
Condition X Group + Condition X Age 1.23 0.223
Condition X Age + Group X Age 3.77 0.063
Condition X Age + Group 4.80 0.038
Group X Age + Condition 9.43 0.004
Saccade curvature
Condition X Age X Group 0.00 0.477
Condition X Age + Condition X Group 1.68 0.206
Condition X Age + Condition X Group + Age X Group 1.73 0.201
Condition X Age +  Group 4.93 0.040
Condition X Age + Age X Group 5.04 0.038
Condition X Age 5.09 0.037  
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